The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

Early studies show a drug can effectively 'switch on' particular cells within the nervous system that play an important role ...

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results ...

Whether these departments get the money will be decided later, but the Scene listened in on requests from the Department of ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Metsera is looking to both improve on that class of drugs, known as GLP-1 inhibitors, as well as offer other options. The ...

Metsera is proving there is still room for the new guy in the GLP-1 world. The seven-month-old startup announced Wednesday it ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...